{"id":"conventional-orlistat-120-mg","safety":{"commonSideEffects":[{"rate":"9%","effect":"Oily spotting"},{"rate":"9%","effect":"Fatty or oily stools"},{"rate":"7%","effect":"Gas with oily spotting"},{"rate":"6%","effect":"Fatty or oily diarrhea"},{"rate":"5%","effect":"Abdominal pain"},{"rate":"4%","effect":"Flatulence"},{"rate":"3%","effect":"Diarrhea"},{"rate":"3%","effect":"Increased bowel movements"},{"rate":"2%","effect":"Nausea"},{"rate":"1%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Orlistat works by inhibiting the enzyme pancreatic lipase, which breaks down fats in the intestine. This leads to a reduction in fat absorption and subsequent weight loss.","oneSentence":"Inhibits pancreatic lipase to reduce fat absorption","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:28:45.628Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Obesity management"}]},"trialDetails":[{"nctId":"NCT06993428","phase":"PHASE2","title":"A Trial With EMP16 in Preparation for Late Phase Studies","status":"NOT_YET_RECRUITING","sponsor":"Empros Pharma AB","startDate":"2025-05-20","conditions":"Overweight or Obese, Obesity and Overweight","enrollment":39},{"nctId":"NCT05934110","phase":"PHASE2","title":"Study Exploring the Supportive Effect of Acarbose in Weight Management","status":"UNKNOWN","sponsor":"Empros Pharma AB","startDate":"2023-04-18","conditions":"Overweight or Obesity","enrollment":320},{"nctId":"NCT06013163","phase":"PHASE1","title":"A Phase 1 Study to Evaluate EMP22 PD and EMP16 PK Versus Xenical® in Healthy Volunteers","status":"UNKNOWN","sponsor":"Empros Pharma AB","startDate":"2023-09-22","conditions":"Overweight or Obesity","enrollment":20},{"nctId":"NCT02503865","phase":"PHASE1, PHASE2","title":"Development of Rational Ways of Medical and Non-medical Treatment Methods for Metabolic Syndrome","status":"COMPLETED","sponsor":"Nazarbayev University","startDate":"2003-01","conditions":"Metabolic Syndrome","enrollment":351}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Xenical"],"phase":"phase_2","status":"active","brandName":"Conventional orlistat 120 mg,","genericName":"Conventional orlistat 120 mg,","companyName":"Empros Pharma AB","companyId":"empros-pharma-ab","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Inhibits pancreatic lipase to reduce fat absorption Used for Obesity management.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}